Bayer and Hurdle launch precision health strategic partnership
- Details
- Category: Bayer
Hurdle, a pioneer in diagnostic testing, and the Consumer Health division of Bayer have launched a strategic partnership to advance consumer innovations in the emerging area of healthy aging. The partnership is designed to enhance the companies' shared ambition to transform self-care through personalized solutions.
Bayer invests 130 million EUR in new production facility for innovative parenteral products
- Details
- Category: Bayer
Bayer has added a brand new manufacturing facility to its global supply chain network. The new production plant was inaugurated today at the company's global pharmaceutical headquarters in Berlin, Germany. The facility features state-of-the-art technology, innovative production, and automated processes.
Pfizer and Astellas' XTANDI® approved by U.S. FDA in earlier prostate cancer treatment setting
- Details
- Category: Pfizer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced that the companies received an approval by the U.S. Food and Drug Administration (FDA) of a supplemental New Drug Application for XTANDI® (enzalutamide), following FDA expedited development and review programs (Priority Review designation, Fast Track designation, Real-time Oncology Review), based on results from the Phase 3 EMBARK trial.
Roche's subcutaneous injection of Tecentriq recommended by the EU's CHMP for multiple cancer types
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of subcutaneous (SC, or under the skin) Tecentriq® (atezolizumab). Tecentriq SC can be injected in approximately seven minutes, with most injections taking between four and eight minutes compared with 30-60 minutes for intravenous (IV) infusion, which can free up time for patients, healthcare teams and caregivers.
Bayer and Recursion focus research collaboration on oncology
- Details
- Category: Bayer
Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of their research collaboration to precision oncology.
The oncology-focused collaboration will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion’s purpose-built artificial intelligence-guided drug discovery platform.
Bayer expands global life science incubator network
- Details
- Category: Bayer
Bayer AG today announced the global expansion of its life science incubator network, Bayer Co.Lab, to Shanghai, China, and Kobe, Japan.
This move establishes new sites for the Bayer Co.Lab program at the hotspots of innovation in China as well as in Japan.
Bayer and Broad Institute of MIT and Harvard extend research collaboration to develop new cancer therapies
- Details
- Category: Bayer
Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments. The expanded agreement will focus on joint cancer target identification and discovery of new therapeutic approaches in oncology.
More Pharma News ...
- AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions
- Pfizer and BioNTech announce positive topline data for mRNA-based combination vaccine program against influenza and COVID-19
- Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
- AskBio contribution to advancing gene therapy highlighted at ESGCT 30th Congress
- FDA approves PENBRAYA™, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents
- CPHI Annual Survey: global pharma resilient with India the chief beneficiary of macro changes
- U.S. FDA approves Pfizer's BRAFTOVI® + MEKTOVI® for BRAF V600E-mutant metastatic non-small cell lung cancer